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Abstract
Mitochondrial Aspects of Neuronal Pathology in Triple-Transgenic
Alzheimer’s Disease Mice
John Z. Cavendish
Alzheimer’s disease (AD) is a fatal, progressive neurodegenerative disease afflicting
millions of people in the United States alone and is the only one of the top leading causes of
morbidity and mortality with no effective disease-modifying therapies. It is the most common
form of dementia, affecting one in three people over the age of 85. While the hallmarks of the
disease include accumulation of beta-amyloid-based extracellular plaques and
hyperphosphorylated tau-based intracellular neurofibrillary tangles, treatment strategies centered
on removing or mitigating these components of AD have all failed in humans. Mitochondrial
dysfunction has been increasingly recognized as an early and consistent pathological feature of
AD. Many questions remain, however, regarding the onset of mitochondrial dysfunction, its
importance to disease progression, and its amenability to treatment to slow or halt progression of
AD. Using a triple-transgenic mouse model of AD, we studied mitochondrial abnormalities in
neurons during the earliest and latest stages of AD pathology. The studies presented in this
dissertation show that mitochondrial dysfunction possibly begins even during neural
development and could be amenable to correction with activation of the sigma-1 receptor, an
intracellular chaperone molecule that enhances mitochondrial function among other
neuroprotective effects. We also show that neuronal mitochondrial number and structure are
largely preserved across multiple brain areas at the very latest stages of AD. The studies
presented herein add to the growing body of evidence of mitochondrial involvement in AD
pathophysiology and suggest possible avenues for clinical translation of mitochondrially-targeted
therapies for AD.
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Chapter 1

Introduction
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Introduction to Alzheimer’s disease
Epidemiology and Impact
Alzheimer’s disease (AD) is the leading cause of dementia and the sixth-leading cause of death in
the United States, but it should be noted that the number of deaths caused by AD are likely
underestimated due to reporting of other illnesses which stem from AD as the primary cause [1]. The
number of people currently afflicted with AD in the United States alone is approaching 6 million, and ten
percent of people 65 and older have AD [1]. At age 85, one in three people will have the disease [1]. With
the increase in elderly individuals from the baby boom generation, these numbers are expected to increase
dramatically. By 2050, it is projected that up to 14 million US adults will have AD if there are no new
breakthroughs in disease prevention or treatment [1]. Roughly two-thirds of AD patients are female, but
the incidence of developing AD appears to be roughly the same between men and women. Women,
however, tend to live longer and have less chance of cardiovascular mortality in middle-age, so a survivor
bias could be the reason for the discrepancy in AD prevalence between the sexes [1].
It has been over a century since the disease was first described, yet AD remains the only one of
the top ten causes of death with no cure and no treatment which slows disease progression. It is also the
only one of the leading causes of death that is consistently increasing in its mortality rate, with at least a
145 percent increase since the year 2000 [1]. Because of the progressive nature, high degree of disability
and dependence, and often long duration of the disease, AD carries a large burden on patients, caregivers,
and the healthcare system. The cost of AD in monetary terms is currently about a quarter of a trillion
dollars per year, and could rise to a trillion dollars per year by 2050, not including an equally high cost of
unpaid caregivers who are often friends, family members, and volunteers [1]. The real burden of the
disease, however, is immeasurable. Throughout the course of AD, patients lose the ability to remember
past experiences, recognize loved ones, carry out daily activities at home and in society, plan for the
future, and emotionally respond to the joys and challenges of life. This is hard for not only the patients,
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but loved ones and caregivers who have a first-hand view of the progressive, yet often unpredictable
deterioration of the mind and body of someone afflicted with AD.
Progression of AD
The clinical symptoms of AD begin with very subtle cognitive changes, sometimes not even
measurable by traditional cognitive screening methods. Patient-reported feelings of cognitive impairment,
known as subjective cognitive decline, are now recognized as a risk factor for development of dementia in
later life [2]. Biomarkers such as Aβ42, total tau, and phosphorylated tau may also be present in
cerebrospinal fluid well before the onset of clinical symptoms and also represent an increased risk of
developing AD [2]. Positron emission tomography (PET) scanning can also detect potential pathological
changes in the very early stages of AD. The two main PET findings are reduced cerebral glucose
metabolism [3] and presence of binding to Aβ of the Pittsburgh compound B (PiB) [4]. The next stages of
AD consist of progressive cognitive impairment that can be detected by clinical cognitive screening
methods. Mild cognitive impairment (MCI) is the first clinically detectable stage, and patients with MCI
are at high risk for developing dementia later in life [2]. MCI manifests differently for different people,
but can include difficulty forming new memories, loss of short-term memory, speech impairment,
difficulty following complex instructions, misplacing items, and a range of effects on ability to carry out
job-related or routine daily activities. As MCI progresses to dementia, patients experience more severe
and profound memory loss, including the inability to recognize people, things, or places that were once
intimately familiar to them. Impairment in the ability to perform activities of daily living lead to
dependence on caregivers or admission to long-term care facilities. Emotional symptoms such as
aggression, frustration, and depression also often occur. In the late stages of disease, AD patients become
increasingly immobile and dependent on care, and often die of secondary causes due to this such as
infections or cardiovascular complications. There is ultimately a 100 percent mortality rate from AD.
Postmortem analysis of brain pathology can differentiate AD from other dementias, but it is noteworthy
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that some people can show all of the brain pathology of AD with no clinical symptoms [5, 6]. Conversely,
some patients with clinical signs of AD do not present significant AD brain pathology [7].
Pathophysiology of AD
Since the 1980s, the National Institutes of Health, primarily through the National Institute of
Aging, have been devoting ever-increasing amounts of funding to AD research. Although important
strides have been made in understanding more about the etiology of AD, the precise mechanisms of AD
pathophysiology are poorly understood, and only a handful of pharmaceutical treatments have been
approved which only modify disease symptoms but do not slow or stop disease progression. When AD
was first described in 1906 by the German physician, Alois Alzheimer, from whom AD gets its name,
two pathological hallmarks were described: extracellular “plaques” and intracellular “tangles” [8]. It is
now known that the plaques of AD stem from aggregation of the beta amyloid (Aβ) peptide which is
cleaved from the membrane-bound amyloid precursor protein (APP) by beta- and gamma-secretases [2].
Extracellular amyloid plaques are perhaps less toxic than the intracellular oligomers of Aβ that form
earlier in disease progression. The neurofibrillary tangles of AD are initiated by and consist primarily of
aggregates of the microtubule-associated protein tau, which is provoked by hyper-phosphorylation at
multiple residues on the protein [9]. Other well-known pathological changes of AD include atrophy of the
cerebral cortex and hippocampus with enlargement of ventricles, loss of synapses, and disruption of
neuromodulatory systems, specifically the cholinergic nucleus basalis of Meynert [10, 11]. More recently,
other pathophysiological changes have been identified in AD, including vascular pathology, increased
inflammation, and metabolic deficiencies related to mitochondria [12-14].
Risk Factors for AD
There are two types of AD—familial, early-onset AD, and sporadic, late-onset AD. Familial AD
is caused by mutations in the genes PSEN1/PSEN2, encoding the presenilin 1 and 2 proteins (PS1 and
PS2) which make up subunits of the gamma secretase complex, and APP, from which Aβ is derived [2].
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Familial AD is dominantly inherited and leads to disease in most cases by the age of 45 [2]. The causes of
sporadic AD are not known, but some genetic and environmental risk factors have been identified. The
biggest risk factor is age, but others include presence of APOE ε4 allele, smoking and lifestyle factors,
diabetes, poor cardiovascular health, and stroke. Some of the hallmarks of Alzheimer’s disease are also
seen in chronic traumatic encephalopathy [15], which further suggests that brain trauma may be a risk
factor for AD. Sporadic AD becomes more common at the age of 65 and increases continuously with age.
Amyloid Cascade Hypothesis and Amyloid-based Treatments
The amyloid cascade hypothesis has been a prominent theory of both sporadic and familial AD
pathophysiology for over 25 years [16, 17]. This hypothesis proposes that increased production and/or
reduced clearance of Aβ, specifically Aβ42 leads to oligomerization of Aβ intracellularly. Intracellular Aβ
oligomers bind to a wide variety of targets in neurons leading to activation of multiple pathways
detrimental to neuronal function and survival. These include impairment of synaptic proteins, increased
reactive oxygen species production, endoplasmic reticulum stress, mitochondrial dysfunction, and
apoptosis. Amyloid oligomers are also thought to bind and activate kinases that phosphorylate tau and
lead to neurofibrillary tangles. Extracellular amyloid plaques which occur in later stages are also thought
to activate the inflammatory response of microglia which further damage synapses and neurons.
There have been several clinical trials of treatments aiming to reduce production or increase
clearance of Aβ to improve AD symptoms and halt disease progression. To date, not a single trial has
produced successful results, and some have had to be stopped early due to worsening outcomes in treated
groups.
In Vitro and Animal Models of AD
Studying the pathophysiology of AD and potential treatments in humans is limited by the fact that
AD likely begins to develop decades before the onset of symptoms, perhaps even during very early brain
development in some cases. Many of the studies needed to document early changes the precede MCI and
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AD would be unethical or impossible in healthy adults. Models allow these barriers to be overcome, but
have their own limitations as well.
In vitro models of AD are useful for studying detailed cellular and molecular biological aspects of
the disease as well as providing an opportunity for high-throughput screening of potential therapeutic
compounds. Applying exogenous Aβ species such as oligomers to cultured neuron-like cell lines or
primary neurons allows studying toxic effects of amyloid [18-20]. Overexpression of mutant tau species,
such as tauP301L, prone to hyperphosphorylation can provide a tool to study the mechanisms and
intracellular effects of neurofibrillary tangle formation in live cells and probe potential treatments [21]. In
vitro models, however, do not allow exploration of the cognitive symptoms of AD or the effects of
treatments on the level of the whole brain and/or organism. The delivery of drugs in in vitro models is not
limited by the pharmacokinetics of whole organisms and do not need to pass through the blood-brain
barrier, so success of compounds in vitro does not always predict that they will be useful for treatment of
AD in vivo.
Animal models can partially overcome the challenges of in vitro models. Most animal models of
AD have been created in mice [22]. Because the etiology of sporadic AD is largely unknown, researchers
used genes mutated in the familial form of AD to recapitulate aspects of AD in transgenic mice. These
mice are therefore not a true model of the more common sporadic AD, but do help the understanding of
how Aβ and/or tau pathology, associated with both sporadic and familial AD, cause downstream effects.
They also offer a vehicle for testing potential treatments at very early stages of AD, before overt
symptoms or neuropathology are present. The first transgenic mouse models used mutant APP or a
combination of mutant APP with PS1, and these mice showed an age dependent development of
extracellular plaques and cognitive deficits similar to human patients. To model neurofibrillary tangles as
well as plaques, additional transgenes were added. One of the most commonly used AD mouse models is
a triple-transgenic AD (3xTg-AD) mouse that was developed by injecting the tauP301L and APPSwe mutant
genes under the Thy1.2 mouse promoter into single-cell embryos from PS1M146V homozygous knock-in
6

mice [23]. This mouse recapitulates both the plaques and tangles of AD as well as cognitive deficits with
aging. The Aβ first accumulates intracellularly, which is associated with synaptic physiological changes,
and then continues to accumulate extracellularly. Finally, intracellular hyperphosphorylated tau pathology
is seen, starting in the hippocampus and progressing to the cortex [24].
Transgenic mice have some disadvantages. One problem is that the insertion of transgenes may
disrupt genes at the insertion point in the genome, which could lead to confounding effects not caused
directly by amyloid or tau pathology. Another problem is that no transgenic model to date has been able
to fully recapitulate every single aspect of human disease. 3xTg-AD mice, for instance, do not show any
increased mortality compared to non-transgenic controls. Nevertheless, mouse models such as 3xTg-AD
mice are valuable tools for understanding the diverse pathways affected in the pathogenesis of AD and for
testing therapeutic strategies which could eventually be translated to prevention or treatment of AD in
humans.
Neuronal Mitochondria
Neuronal Energy Production
The human brain is remarkably energy-dependent, using 20% of the body’s energy while
occupying only 2% of its mass [25]. The high adenosine triphosphate (ATP) demand of electrical
signaling in its estimated 86 billion neurons is largely responsible for this energy dependence. There are
16 billion neurons in the cerebral cortex alone, and each cortical neuron uses an average of 4.7 billion
ATP molecules per second [26]. Oxidative phosphorylation in the mitochondria using fuel supplied by
glucose and ketone bodies is the main source of neuronal ATP [27], and it follows that mitochondria are
critical for the survival and proper functioning of neurons. Disorders of mitochondrial function or
impairments in glucose and oxygen delivery are especially detrimental to neuronal survival [28, 29].
Mitochondrial Biogenesis, Distribution, and Function in Neurons
Mitochondria are presumed to arise in the cell body of neurons, but in some cases could be
synthesized distally in the axon [30]. The majority of mitochondrial proteins are encoded by nuclear DNA
7

and synthesized on ribosomes in the cytosol [31, 32]. Mitochondria distribute along axons and dendrites
of neurons, with differences in morphology and spacing between the two compartments [33, 34].
Dendrites are more densely populated, with longer mitochondria, and axons are more sparsely populated
with shorter mitochondria. There does not appear to be a bias for mitochondrial localization at synapses in
general [33], but there does appear to be activity-dependent distribution [35]. One can imagine how such
distribution would be beneficial given the functions of neuronal mitochondria. In the distal neurites,
mitochondria produce ATP which acts locally to power ion pumps that maintain membrane potential and
counteract synaptic ion fluxes [27]. Mitochondrial ATP also helps neurons meet the anabolic demand of
shaping synapses [36]. In addition to producing ATP, mitochondria take part in calcium homeostasis [37]
and apoptosis signaling [38]. Mitochondria can also tether to the endoplasmic reticulum where the two
organelles signal to one another, but the consequences of such signaling and the pathways involved are
only beginning to be unraveled [39].
Mitochondrial Dynamics
Neuronal mitochondria are dynamic organelles that are transported along the cytoskeleton of
neurites in anterograde and retrograde directions [33, 40-43]. The average speed of motile mitochondria
in neurons is reported to vary from 0.32 – 0.91 μm/sec [44], with roughly one third of mitochondria
moving at any time and the rest stationary [33, 45]. Traditional motor proteins, dynein and kinesin, drive
mitochondrial movement over long distances in the cell but depend on mitochondria-specific adaptor
proteins named milton (in mammals TRAK1 and TRAK2) [46] and miro (mitochondrial Rho GTPase)
[47] to bind to mitochondria. Miro is anchored to the mitochondrial outer membrane, while TRAK1/2
link miro to the motor proteins [44]. The majority of long-distance mitochondrial trafficking is facilitated
by microtubules, but thin actin filaments may enable local trafficking [48]. Stationary mitochondria are
anchored to the cytoskeleton [49-52] and a putative axonal docking protein, syntaphilin, was recently
described . Expression of syntaphilin promotes a higher percentage of stationary mitochondria, whereas
knockdown of syntaphilin enhanced mitochondrial motility in axons [53].
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In addition to movement along the cytoskeleton, mitochondria undergo fission and fusion. Fusion
of the outer membrane requires mitofusins 1 and 2 (MFN1 and MFN2) [54, 55] and OPA1 allows fusion
of the inner membrane [56]. A dynamin-related protein, DRP1, is largely responsible for mitochondrial
fission [57]. DRP1 forms a constricting spiral upon activation which pinches off the inner and outer
mitochondrial membrane [58]. Another outer membrane protein, Fis1, is thought to be involved in
recruitment of DRP1, but Fis1 is not necessary for fission [59]. The purpose of mitochondrial fission and
fusion is debated, but it is hypothesized that fusion, followed by redistribution of proteins and other
membrane components, and then asymmetric fission, leads to replenishment of one mitochondrion at the
expense of the slightly more depolarized sister mitochondrion that is later degraded [60].
Mitochondrial Degradation
Mitochondria experience constant turnover, with a measured in-vivo half-life of 24.4 days for rat
brain mitochondria, independent of age [61]. Because neurons are mostly non-dividing cells and
mitochondria become damaged over time, mechanisms must exist for damaged mitochondria to be
removed to prevent accumulation of reactive oxygen species (ROS) [62] which cause neuronal insult.
Mitophagy is a mitochondrially-directed autophagocytic process which removes damaged mitochondria
via lysosomal degradation. As would be expected, pharmacological insult of mitochondria in cultured
cortical neurons leads to upregulation in mitophagy [63]. Like biogenesis, mitophagy is presumed to
occur in the cell body, but a notable exception has been observed in distal axons of cultured neurons [64].
In summary, the cycle of mitochondrial synthesis, anterograde translocation, arrest, retrograde
translocation, fission, fusion, and degradation is central to neuronal survival and plasticity. Disruption of
this balance is likely a key factor in neurodegeneration including in AD.
Mitochondrial Dysfunction in Alzheimer’s Disease
Mitochondrial dysfunction, which is a known consequence of many cellular insults, is
increasingly recognized as a critical step in the pathological cascade leading to the AD phenotype [17,
65]. AD patients show reductions in cerebral glucose metabolism in areas associated with AD pathology
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including hippocampus, parietotemporal cortex, and cingulate cortex years before the onset of AD
symptoms by FDG-PET imaging [3, 66]. Homologous regional alterations in brain metabolism are seen
early in life in the triple-transgenic Alzheimer’s disease (3xTg-AD) mouse model of AD, and by 18
months all brain areas show reduced glucose metabolism [67]. Human AD patients also show alterations
in TCA cycle enzymes in the brain including reduced activity of pyruvate dehydrogenase, isocitrate
dehydrogenase, and alpha-ketoglutarate dehydrogenase and increased activity of succinate dehydrogenase
and malate dehydrogenase [68, 69]. These alterations correlate strongly with the clinical stage of disease.
The 3xTg-AD mouse similarly shows reduced pyruvate dehydrogenase protein levels and mitochondrial
respiration in the brain as early as 3 months of age and reduction in mitochondrial respiration of
embryonic primary hippocampal neurons [70]. AD patients are frequently found to have mtDNA
mutations or deletions [71], and cybrid studies where mtDNA from peripheral cells of AD patients is
expressed in mtDNA-depleted cultured cells demonstrate bioenergetic deficits in the AD cybrid cells [72].
Mitochondrial dysfunction is also seen in the only nontransgenic AD rodent model, where streptozocin
injected intracerebrovascularly promotes neuroinflammation, amyloid-beta accumulation, and cognitive
changes [73, 74].
Mitochondrial movement could also be affected in AD. Abnormalities in axonal transport and
axonal swellings are observed early in AD in humans and mouse models [75], implying that mitochondria
and other organelles may not be able to distribute normally in those neurons. We and others previously
showed that exogenously applied Aβ oligomers can impair mitochondrial movement and cause a
reduction in mitochondrial size in primary hippocampal neurons [18-20] and more recently that
mitochondrial movement was greatly impaired in 3xTg-AD primary cortical neurons [Cavendish et. al;
Article Accepted, Awaiting Publication].
Mitochondria may also be structurally abnormal even before neurodegeneration is evident. Two
studies of AD patients showed reduction in number of neuronal mitochondria [14, 76]. Changes to
neuronal mitochondrial structure, including reduced mitochondrial size, were seen in the hippocampus,
auditory cortex, and frontal cortex, as well as several other non-AD associated brain areas of AD patients
10

[76]. Abnormal mitochondrial structure, including paracrystalline inclusions between mitochondrial
cristae and increased matrix density, was also seen in dendrites of neurons in the frontal cortex of AD
patients [77]. Interestingly, the presence of abnormal mitochondria in this study coincided with cortical
areas with more severe dendritic degeneration. One study described a unique mitochondrial structural
phenotype resembling “mitochondria on a string” in the hippocampus and entorhinal cortex of human AD
patients as well as in the hippocampus of various strains of transgenic AD mice [78]. An in vivo study of
mitochondrial structure in APP/PS1 mice showed reduced mitochondrial density and abnormal
mitochondrial structure in the immediate vicinity of amyloid plaques [79].
AD-associated mitochondrial deficits are often attributed to the mito-toxic effects of beta amyloid
[80-84], yet, as mentioned, amyloid-based treatments have thus far been unsuccessful in ameliorating the
symptoms or progression of AD in humans. One probable reason for the failure of these strategies is that
treatment begins too late in the progression of the disease, when significant neuronal damage has already
occurred. Another potential reason is that beta amyloid accumulation is only part of a cascade of events
leading to mitochondrial damage, which manifests as reduced bioenergetic capacity, impaired
mitochondrial dynamics, elevated reactive oxygen species, synaptic dysfunction and loss, and increased
apoptosis of AD neurons. While beta amyloid may indeed initiate this cascade, the effects of impaired or
damaged mitochondria could positively feedback to invoke even more mitochondrial damage, leading to a
vicious cycle. It is likely that these mitochondria-mediated stresses are both necessary and sufficient to
cause neurodegeneration, and AD treatments should therefore aim to protect and restore mitochondrial
function in addition to alleviating other known pathways of neuronal damage. Removing beta amyloid or
blocking its effects would only be efficacious before significant mitochondrial damage has occurred.
In addition to alterations of levels and activity of mitochondrial enzymes, changes to
mitochondrial structure, and impaired mitochondrial dynamics, many other mechanisms may underlie
AD-associated metabolic deficits. Studying mitochondrial structure, number, distribution, dynamics, and
function in AD neurons both in vitro and in AD animal models can provide more insight into multiple
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mechanistic pathways and lead to new treatment strategies to protect against mitochondrial damage in the
early stages of AD and restore mitochondrial function in advanced AD patients.
Sigma-1 Receptors for treatment of Alzheimer’s Disease
Compounds which act to prevent or counteract mitochondrial deficits could be useful tools to
protect neurons from the irreversible damage that occurs in the progression of AD. Sigma-1 receptor
(σ1R) agonists are a promising drug class to achieve enhanced mitochondrial function among other
neuroprotective effects [85]. The σ1R is a chaperone protein present in neurons within mitochondrial,
nuclear, and plasma membranes. In the inactive state, σ1Rs are found in the mitochondrial associated
membrane (MAM) of the endoplasmic reticulum (ER) bound to the heat shock 70 protein BiP [38]. Once
activated, σ1Rs dissociate from BiP and increase Ca 2+ efflux from the ER through IP3 receptors at the
MAM [86, 87]. Mitochondria then take up Ca 2+ leading to activation of tricarboxylic acid cycle
enzymes and enhancement of oxidative phosphorylation.
Although exogenous σ1R ligands are not related structurally, several have been identified as
selective, high affinity σ1R agonists, such as (+)SKF-10,047 [(+)-N-Allylnormetazocine hydrochloride], a
member of the benzomorphan drug class. σ1R agonists have shown promise for treatment of AD in
preclinical studies [88-90], but whether they exert these effects through mitochondrial mechanisms
remains to be fully elucidated. In one of the studies described here, we provide evidence that a σ1R
agonist can indeed partially restore mitochondrial function in an in vitro model of AD. ANAVEX 2-73, a
sigma agonist, is currently in phase II of a clinical trial for treatment of AD, and more compounds are
continually being developed which may counteract various aspects of AD.
Other mechanisms of σ1R neuroprotection in AD include attenuation of ROS production [89, 90],
inhibition of ER stress [87, 91], protection from apoptosis [90, 92], reduction in inflammatory activation
of glia [93], and prevention of tau hyperphosphorylation via glycogen synthase kinase 3β (GSK3β) [94].
All of these factors make σ1R agonists promising candidates for treating multiple aspects of AD
pathology and warrant further in vivo and clinical study of these compounds.
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Gaps in Knowledge
There are many unknown aspects of the pathophysiology of AD. Of the many hypotheses
explaining the initiating factors and key steps in the development of AD pathology, none have
successfully explained all aspects of the disease. The amyloid hypothesis may account for familial AD,
but falls short in sporadic AD where it fails to explain why some individuals who exhibit extensive AD
pathology have clinically normal cognition, or why some individuals with all of the clinical symptoms of
AD show little to no AD pathology [95]. The mitochondrial cascade hypothesis proposes that major
differences exist between the pathophysiology of familial AD versus sporadic AD, and that in sporadic
AD, Aβ is more of a marker of brain aging than the initial driving factor of disease [17]. This hypothesis,
however, does not explain why AD does not occur concurrently with every mitochondrial or metabolic
disease. Tau-centric hypotheses propose that tau hyperphosphorylation and aggregation into fibrils is the
driving force of AD pathology and is the final common pathway of a variety of insults, including ROS,
heavy metal toxicity, Aβ oligomers, and cholesterol/LDL dysregulation, which activate microglia to
damage neurons and synapses [96]. Tau hypotheses also fall short of encapsulating the full explanation
for AD, as not all tauopathies lead to AD clinical symptoms or amyloid pathology, such as frontotemporal
dementia with mutant tau.
One explanation for the lack of any single hypothesis to explain AD pathophysiology is that
familial AD has a separate etiology from sporadic AD, and sporadic AD could actually describe several
related multifactorial diseases with similar outcomes [97]. There is evidence for this in the fact that AD
biomarkers exhibit several different profiles with distinct clinical features. For example, AD cases having
low Aβ1-42 in CSF and presence of the APOE ε4 allele (AELO) have later onset than AD with low Aβ1-42
and high tau in CSF (ATEO) [97]. More research is needed in understanding the heterogeneity of
sporadic AD, and perhaps with improved biomarkers and imaging techniques combined with longitudinal
studies of large patient populations even more subtypes of AD might be identified.
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Another issue in the field of AD research is the overall failure of putative AD treatments in
humans. Currently, the only approved drugs for AD are the cholinesterase inhibitors donepezil,
rivastigmine, and galantamine, and the NMDA receptor antagonist memantine. These medications only
improve symptoms of AD, but do nothing to slow or stop the ultimate progression of the disease. There
have been over 400 clinical trials for AD drugs, but nearly all have ultimately failed to make an impact on
AD progression. As of 2018, there were 112 compounds in AD clinical trials: 26 in phase III, 62 in phase
II, and 23 in phase I [98]. Of the phase III trials for disease modifying agents, nearly all are amyloidbased treatments due to the historical focus on Aβ as the main driver of AD pathology. Phase I and II
trials contain a wider variety of agents, including compounds with anti-inflammatory, metabolic
modifying, neuroprotective, and neuroregenerative actions.
While the future of AD clinical trials appears more promising than the past, problems and
questions still exist with the development of AD therapeutics in general. A major concern of past and
current trials is that by the time treatment begins in symptomatic AD patients, it is likely that the disease
has been ravaging the brain for many years and that significant, irreversible loss of neurons and synapses
has already occurred. AD-associated vascular damage may further complicate delivery of therapeutics, as
preliminary data from our lab has shown an extensive and selective loss of small diameter vessels in
3xTg-AD mice (Quintana et. al; publication in revision) and AD patients often have cerebral amyloid
angiopathy or other concurrent neurovascular damage. The multifactorial nature of AD also makes it
unlikely that any monotherapy targeting one specific pathway can fully treat all aspects of AD pathology
[97]. Earlier identification of individuals at high risk of developing AD combined with more chronic
administration of drugs could be beneficial, but these types of trials present more risk of harm to
otherwise healthy patients, high costs, and high turnaround time until results are known. It has also been
proposed that strategies using pharmaceutical agents targeting multiple pathways, using multiple drugs in
combination, and/or stratification of patients into different subtypes of AD could all help overcome the
barriers to AD treatment [99].
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Summary and Conclusions
With the ever-growing population of AD patients, the substantial reduction of their quality of life
and years of life lived, and increasing burden on caregivers and healthcare providers, AD is becoming an
increasingly harrowing problem requiring more research to understand its causes and develop diseasemodifying agents. New approaches informed by the mistakes of the past decades are needed which
acknowledge the multifactorial and heterogeneous nature of the disease as well as the potential that the
pathological changes leading to AD often begin many years before clinical symptoms are apparent.
Metabolic and mitochondrial abnormalities are among the earliest changes in AD, and there is
significant evidence that mitochondrial damage is a critical step in AD progression. Transgenic mice and
in vitro models of AD provide robust opportunities for studying the diverse changes to mitochondrial
biogenesis, structure, dynamics, and function in the pathogenesis of AD. They also allow testing of
compounds for ameliorating AD pathology via modulation of mitochondria. Translational research of
mitochondria in AD can help the development of compounds that can be used alone or as part of multidrug regimens in the prevention and treatment of AD.
The purpose of the work in this dissertation was to understand the very late and very early
mitochondrial changes in AD using a mouse model of the disease. I examined mitochondrial morphology,
number, and movement in embryonic cortical neurons from 3xTg-AD mice to understand if
mitochondrial changes occurred at the very earliest stage of potential disease, during neuronal
development, and see if mitochondrial deficits were responsive to treatment with a σ1R agonist. I also
performed a large-scale microscopic analysis of mitochondria in various brain areas of aged 3xTg-AD
mice at the latest stages of AD to identify the pathological correlates of mitochondrial morphology,
number, and distribution. Together these aims helped to inform the mitochondrial aspects of AD and
evaluate the potential for early amelioration of AD mitochondrial pathology in at-risk populations and
enhancement of mitochondrial function late in disease progression.
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ABSTRACT
Mitochondrial dysfunction is often found in Alzheimer’s Disease (AD) patients and animal
models. Clinical severity of AD is linked to early deficiencies in cognitive function and brain
metabolism, indicating that pathological changes may begin early in life. Previous studies
showed decreased mitochondrial function in primary hippocampal neurons from triple-transgenic
Alzheimer’s disease (3xTg-AD) mice and mitochondrial movement and structure deficits in
primary neurons exposed to amyloid beta oligomers. The present study characterized
mitochondrial movement, number, and structure in 3xTg-AD primary cortical neurons and nontransgenic (nonTg) controls. We found a significant reduction in mitochondrial number and
movement in 3xTg-AD primary cortical neurons with modest structural changes. Additionally,
application of the sigma-1 receptor agonist, (+)SKF-10,047, markedly increased mitochondrial
movement in both 3xTg-AD and nonTg primary cortical cultures after one hour of treatment.
(+)SKF-10,047 also led to a trend of increased mitochondrial number in 3xTg-AD cultures.
Embryonic mitochondrial movement and number deficits could be among the key steps in the
early pathogenesis of AD that compromise cognitive or metabolic reserve, and amelioration of
these deficits could be a promising area for further preclinical and clinical study.
Keywords: Alzheimer’s Disease, Mitochondrial Size, Mitochondrial Dynamics, Sigma
Receptors

17

INTRODUCTION
Alzheimer’s disease (AD) is characterized by a progressive decline in cognition, atrophy
of cerebral cortex and hippocampus, loss of synapses, and disruption of neuromodulatory
systems [11, 100]. Histopathological hallmarks of AD include amyloid-beta (Aβ) peptide
aggregates and hyperphosphorylated tau-related neurofibrillary tangles, but the contribution of
these neuropathological features to the emergence of AD symptoms, especially cognitive
decline, is still unclear [101]. Growing evidence suggests that mitochondrial dysfunction is a
critical step in the pathological cascade leading to the AD phenotype [17, 102]. AD patients and
at-risk individuals show early regional hypometabolism throughout the cerebral cortex and
hippocampus [3]. Mitochondrial structural abnormalities including reduced mitochondrial size
have also been reported in brains of AD patients [76, 77] and mouse models [78]. Reduced levels
and activity of tricarboxylic acid cycle enzymes in AD brain tissue have been reported [69], and
there is a reduction in mitochondrial number in pyramidal neurons in AD patients, corresponding
to an increase in mitochondrial DNA within autophagocytic cytoplasmic granules [14]. Reduced
mitochondrial number was also seen in M17 cells overexpressing wild-type or mutant APP
[103]. Further, AD patients often harbor mitochondrial DNA mutations or deletions [104].
The triple transgenic Alzheimer’s disease (3xTg-AD) mouse has three mutations
(PS1M146V/APPSwe/tauP301L) associated with early onset AD in humans [23]. This mouse mimics
the human AD phenotype, with progressive Aβ production, tau hyperphosphorylation, and
neurofibrillary tangle formation across the cortex and hippocampus as well as accelerated
cognitive decline [24]. Like human patients, 3xTg-AD mice exhibit early bioenergetic deficits,
including reduced ATP production in embryonic hippocampal neurons [70]. We and others
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previously showed that exogenously applied Aβ oligomers can impair mitochondrial movement
and cause a reduction in mitochondrial size in primary hippocampal neurons [18-20].
3xTg-AD primary cortical neurons express detectable levels of Aβ as early as 7 days in vitro
(DIV), and Aβ increases with time in culture [105]. Prior to this study, it was not known whether
the early expression of Aβ in 3xTg-AD neurons would cause the same mitochondrial phenotypes
seen in primary neurons exposed to exogenous Aβ. To probe this question, we measured
mitochondrial structure, number, and movement in primary cortical neurons from 3xTg-AD mice
and non-transgenic (nonTg) controls. We hypothesized that 3xTg-AD neurons would exhibit
impairment in mitochondrial movement along neurites, reduced mitochondrial size, and
increased roundness compared to nonTg mice. We also hypothesized that there would be
decreased mitochondrial number in 3xTg-AD neurons similar to the reduction observed in
human AD patients [14].
Compounds which act to prevent or counteract mitochondrial deficits could be useful
tools to protect neurons from the irreversible damage that occurs in the progression of AD.
Sigma-1 receptor (σ1R) agonists are a promising drug class to achieve enhanced mitochondrial
function among other neuroprotective effects [85]. The σ1R is a chaperone protein present in
neurons within mitochondrial, nuclear, and plasma membranes. In the inactive state, σ1Rs are
found in the mitochondrial associated membrane (MAM) of the endoplasmic reticulum (ER)
bound to the heat shock 70 protein BiP [106]. Once activated, σ1Rs dissociate from BiP and
increase Ca2+ efflux from the ER through IP3 receptors at the MAM [86, 87]. Mitochondria then
take up Ca2+ leading to activation of tricarboxylic acid cycle enzymes and enhancement of
oxidative phosphorylation. Although exogenous σ1R ligands are not related structurally, several
have been identified as selective, high affinity σ1R agonists, such as (+)SKF-10,047 [(+)-N19

Allylnormetazocine hydrochloride], a member of the benzomorphan drug class. σ1R agonists
have shown promise for treatment of AD in preclinical studies [88-90], but whether they exert
these effects through mitochondrial mechanisms remains to be fully elucidated.
To gain more insight into this question, we studied the effects of σ1R activation on
mitochondrial structure, number, and movement in primary cortical neurons from 3xTg-AD and
nonTg mice using (+)SKF-10,047. Movement of mitochondria along microtubules is carried out
through kinesin and dynein proteins, which require ATP for their function [107]. Decreased ATP
production, as seen in AD neurons, could impair mitochondrial movement. σ1R activation can
increase oxidative phosphorylation, which could provide added energy for mitochondrial
movement. Therefore, we hypothesized that (+)SKF-10,047 would increase mitochondrial
movement in primary cortical neurons. Additionally, σ1R agonists can protect against the
intracellular stressors that lead to mitochondrial fragmentation and reduced mitochondrial
number through multiple downstream effects of σ1R activation [108]. We hypothesized that
(+)SKF-10,047 would increase mitochondrial size and number in primary cortical neurons while
reducing mitochondrial roundness.
MATERIALS AND METHODS
Mice
Animal protocols were performed in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of West Virginia University. Homozygous 3xTg-AD and
nonTg controls (C57BL6/129S) were obtained from The Jackson Laboratory, and colonies were
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bred and maintained at West Virginia University. Animals were housed in cages of up to five
animals on a 12-hour light cycle with ad libitum access to food and water.
Primary cortical culture
Pregnant mice were anesthetized with isoflurane and euthanized by cervical dislocation at
E18.5. Brains of pups were removed and placed in ice-cold Hank’s Balanced Salt Solution
(HBSS). Cortices were dissected and meninges were removed with fine forceps before
transferring to neurobasal culture medium (Gibco) supplemented with 2% B-27 (Gibco), 1%
pen-strep (HyClone), and 1% Glutamax (Gibco). Cortices were triturated 10-15 times with a 5
mL pipette followed by a series of three flame-polished Pasteur pipettes with increasingly
narrow tip diameter before being filtered through a 70 μm nylon cell strainer (Falcon). Cells
were plated on poly-L-lysine (Sigma) coated 35 mm glass-bottom dishes (glass diameter 23mm,
thickness 0.17mm; World Precision Instruments) at a density of 7.5 x 105 cells in 2 mL of
medium and maintained in a 95% humidity, 5% CO2, 37oC incubator for up to two weeks. At 2
DIV, 1-beta-D-arabinofuranosylcytosine (AraC; Sigma) was added at a final concentration of 4
μmol/L to inhibit glial growth. Subsequently, half of the culture medium was replaced every
three days.
Mitochondrial labeling
Mitotracker® Red CMXRos
Immediately prior to imaging, media was replaced with 80 nmol/L Mitotracker® Red
CMXRos (MT-Red; Thermo Fisher Scientific) in complete neurobasal media and incubated for
15 min at 37oC. MT-Red solution was then removed and replaced with the culture-conditioned
media in which cells had been growing prior to staining.
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pDsRed2-Mito vector
pDsRed2-Mito vector (Clontech) was amplified using GT115 competent E. coli cells
(InvivoGen) and isolated with a Midiprep kit (Thermo Fisher Scientific). For each transfection, 8
μg of plasmid DNA was diluted in 100 μL serum-free Opti-MEM I (Thermo Fisher Scientific).
10 μL Lipofectamine-2000 (Thermo Fisher Scientific) was diluted in 100 μL serum-free Opti
MEM I and allowed to stand for 10 min at room temperature. The plasmid and lipofectamine
solutions were combined, gently mixed, and allowed to stand for 20 min at room temperature
before application to cultures. Cells were transfected at 12.5 DIV. Cultures were imaged 36
hours post-transfection.
Preparation of (+)SKF-10,047
(+)SKF-10,047 (Tocris) was dissolved in sterile milliQ water to create a 10mM stock
solution which was aliquoted and stored at -20oC. Just prior to application to cells, a 2 μmol/L
working solution was made by diluting the stock solution 1:5000 in pre-warmed complete
neurobasal media. Vehicle controls (Veh) were made by diluting sterile milliQ water 1:5000 in
pre-warmed complete neurobasal media.
Live-cell imaging
The investigator performing imaging experiments was blinded to treatment group (Veh or
SKF). Widefield imaging was performed on a Nikon Eclipse TE2000-E microscope with an oil
immersion 60x Apochromat DIC objective (Nikon) with 1.49 numerical aperture. Neither a
polarizer nor an analyzer was used. The microscope’s 1.5x magnification lens was used to give a
final magnification of 90x. A halogen light source was used with an ND4 neutral density filter,
an ET555/25x excitation filter, and an ET605/52m emission filter (Chroma Technology Corp.) to
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image mitochondria stained with MT-Red or pDsRed2-Mito vector. For comparisons of 3xTgAD and nonTg cultures at 12-14 DIV, fluorescence images were captured with an exposure time
of 60ms (MT-Red-stained cultures) or 300ms (pDsRed2-Mito-stained cultures) on a CoolSNAP
monochrome CCD camera (Photometrics) with 2x2 binning and 1024x1024 resolution giving a
pixel size of 141 nm. For experiments at 7-9 DIV, fluorescence images were captured with an
exposure time of 60ms on an ORCA CMOS camera (Hamamatsu) with 2x2 binning and
2048x2048 resolution giving a pixel size of 72 nm. During imaging, cultures were maintained in
a humidified digital stage-top incubator (OKO Labs) at 37oC and 5% CO2.
Imaging of DIV12-14 cultures
For structural imaging of MT-Red-stained DIV12-14 cultures, eight single-plane images
of 143.36 μm x 143.36 μm were captured at equidistant points along a circle midway between
the center of the culture and the culture edge. For DIV14 pDsRed2-Mito-transfected cultures, an
individual transfected neuron was selected. Time-lapse images from five non-overlapping fields
of view containing separate proximal neurites at varying distances within 10-100 μm of the cell
body were acquired every 15 seconds for one hour.
Imaging of DIV7-9 cultures and treatment with (+)SKF-10,047
For DIV7-9 cultures, time-lapse images were acquired at five non-overlapping fields of
view approximately 250 μm apart every 30 seconds for 30 minutes starting at a point halfway
between the center of the culture and the culture edge. Fifteen single-plane images were then
captured along a circle halfway between the edge and center of culture. Half of the culture
medium was then replaced with vehicle or (+)SKF-10,047-containing medium to achieve a final
concentration of 1μmol/L. We chose this concentration based on the EC50 value of 0.8 μmol/L
(+)SKF-10,047 previously reported for in vitro studies of neuroprotection [109]. One hour post23

treatment, fifteen more single-plane images were captured halfway between the center of the
culture and the culture edge at points that had not previously been imaged. Finally, a 30-minute
post-treatment time-lapse series was captured in the same way as pre-treatment comprising five
fields of view that had not been previously imaged separated by approximately 250 μm.
Image analysis
Investigators performing data analysis were blinded to treatment group and genotype.
Mitochondrial structure and number
Images were exported from their native ND2 formats to 16-bit TIFF files using NIS
elements (Nikon). Mitochondrial size, width, and number were calculated using an automated
Matlab program generously provided by P.M. McClatchey which has been previously described
[110] (Supplementary Figure 2.1A). Mitochondrial roundness (inverse of aspect ratio) was
calculated by dividing width by height, with a value of 1 corresponding to a perfect circle and 0
corresponding to an infinitely long polygon in 1 dimension. A total of four fields of view per
culture were used for DIV12-14 cultures and eight fields of view were used for DIV7-9 cultures.
Odd numbered images were selected for analysis unless they contained putative glial cells, as
identified by lack of neurites and a reticular network of mitochondria (Supplementary Figure
2.1B). If a glial cell was present, the closest even-numbered image was used for analysis.
Individual mitochondrial measures from all four (DIV12-14) or eight (DIV7-9) fields of view of
a culture were combined and averaged to give average length, width, and roundness for that
culture. The total number of mitochondria was divided by the combined imaging area to yield
number of mitochondria per square micron. Each culture was treated as an independent n.
Mitochondrial movement analysis in pDsRed2-Mito-transfected neurons
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Analysis was carried out in NIS elements (Nikon). Time-lapse images were aligned, and
the advanced de-noising function was used with de-noising power of 50 followed by rolling ball
background subtraction (radius = 1 μm). Five 1.1 μm by 6 μm regions of interest (ROIs) were
placed orthogonal to proximal neurites between 10 μm and 100 μm from the cell body. The ROI
width was chosen based on a previously described method for tracking mitochondrial occupancy
along neurites [33]. A time measurement of maximum fluorescence intensity within ROIs was
then performed. Only the first 15 minutes of imaging were included to minimize potential
phototoxicity effects. Mitochondrial movement events were defined as an increase or decrease of
maximum fluorescence intensity of at least 200 fluorescence units over 30 seconds or less,
corresponding to mitochondrial movement into or out of the ROI (Supplementary Figure 2.2A).
Mitochondrial transit events, defined as a movement event in which a mitochondrion passed
completely from one side of the ROI to the other, were manually counted (Supplementary Figure
2.2B).
Mitochondrial movement analysis in Mitotracker® Red CMXRos-stained neurons
Time-lapse images were aligned in NIS elements and exported as stacks of 16-bit TIFF
files. Despeckling, background subtraction (rolling ball method; radius = 20 pixels), and autothresholding using the Otsu method were performed in FIJI (NIH) to create binary masks. One
300 pixel by 300 pixel (21.6 μm x 21.6 μm) subregion was randomly generated within each
image using a random number generator in Excel (Microsoft) for x and y coordinates. If the
subregion contained part of a cell body or out-of-focus material, a new region was randomly
generated until only in-focus neurites were found within the region. The subregion was cropped
and imported into Imaris (Bitplane). Manual spot tracking of every mitochondrion present within
the subregion for at least two frames (1 min) was performed. Tracking consisted of placing a dot
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at the object’s center of mass starting at the first frame where it was visible until it (1)
disappeared from the edge of the field of view; (2) disappeared for more than 3 consecutive
frames without reappearing in the same location during that time; or (3) fused with another
object for at least 3 consecutive frames. In the case of fusions, the larger of the two objects
continued to be tracked while the smaller object stopped being tracked at the time of fusion. If an
object split from another object for at least 3 frames, it was counted as a new object and tracked
from the first frame of clear separation from the other object. After all objects were tracked,
measurements were exported and average velocity of each spot was calculated by dividing total
displacement by track duration. One subregion was tracked in each field of view, and three fields
of view were analyzed for each culture. All objects’ velocities from the three fields of view were
pooled and averaged to give an average mitochondrial velocity for each culture.
Statistical analysis
All statistical analyses were performed using Prism version 7.04 (GraphPad). Two-tailed
unpaired t-tests were used to assess the effect of genotype on mean mitochondrial length, width,
roundness, number/μm2, movement events/min, transits/min, and velocity between nonTg and
3xTg-AD cultures with a significance level of p<0.05. For structure and number measurements
in DIV12-14 cultures, n=11 nonTg and n=11 3xTg-AD cultures spread across three separate
pregnancies each were compared. For movement measures in DIV14 cultures, n=8 nonTg and
n=7 3xTg-AD cultures (one neuron per culture) spread across three pregnancies each were
compared. For structure, number, and movement measures in DIV7-9 cultures, pre-treatment
values from n=6 nonTg and n=6 3xTg-AD cultures from one pregnancy each were compared.
Two-way analysis of variance (ANOVA) was used to assess effect of genotype (nonTg vs. 3xTgAD) and treatment (Vehicle or (+)SKF-10,047) on mitochondrial structure, number, and velocity
26

one hour post-treatment in DIV7-9 cultures with a significance level of p<0.05. Two-tailed ttests were used to probe effects of treatment within genotypes if significant interaction between
genotype and treatment were observed with ANOVA. n=3 cultures per group were used for each
treatment and genotype and were derived from one pregnancy for each genotype.
RESULTS
Mitochondrial structure and number in 3xTg-AD cortical neurons at 12-14 DIV.
Within individual cultures, mitochondria ranged widely in shapes and sizes including
small spheres, larger ovoid shapes, rods of varying length, and branching filaments (Fig.
2.1A,B). However, average mitochondrial size, number, and roundness remained fairly
consistent across different cultures within each group as long as a sufficient number of fields of
view were sampled. At 12-14 DIV, mitochondrial length was significantly reduced in 3xTg-AD
cultures (t(20) = 5.108, p<0.0001) (Fig. 2.1C). Mitochondrial width showed a marginal tendency
toward being increased in 3xTg-AD cultures (t(20) = 2.024, p=0.0565) (Fig. 2.1D). Consistent
with these observations, mitochondrial roundness was significantly increased in 3xTg-AD
cultures compared to nonTg cultures (t(20) = 5.568, p<0.0001) (Fig. 2.1E). The most pronounced
difference between cultures was a decrease in mitochondrial number in 3xTg-AD cultures (t(20)
= 4.226, p=0.0004) (Fig. 2.1F).
Mitochondrial movement in neurites of 3xTg-AD cortical neurons at 14 DIV.
Mitochondrial movement was assessed in neurites of pDsRed2-mito transfected neurons
at 14 DIV using ROIs placed 10-100 μm from the cell body (Fig 2.2A,B). Movement events
were significantly reduced in 3xTg-AD neurites compared to nonTg controls (t(13) = 2.942,
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p=0.0115) (Fig 2.2C). There was also a reduction in number of passing mitochondria per minute
in 3xTg-AD neurites (t(13) = 3.069, p=0.0090) (Fig 2.2D).
Mitochondrial structure and number in 3xTgAD cortical neurons at 7-9 DIV
Mitochondrial number and structure were compared in nonTg and 3xTg-AD neurons at
7-9 DIV (Fig. 2.3A,B). There was no significant difference in mitochondrial length between
nonTg and 3xTg-AD cultures (Fig. 2.3C). Mitochondrial width was significantly increased in
3xTg-AD neurites at 7-9 DIV (t(10) = 3.962, p=0.0027) (Fig. 2.3D). Mitochondrial roundness
was slightly but significantly decreased in 3xTg-AD cultures (t(10) = 3.609, p=0.0048) (Fig.
2.3E). Similar to DIV12-14 cultures, 3xTg-AD cultures at 7-9 DIV had significantly fewer
mitochondria per square micron than nonTg cultures (t(10)=9.316, p<0.0001) (Fig. 2.3F). The
percent decrease in mitochondrial number in 3xTg-AD cultures at 7-9 DIV was similar to the
change at 12-14 DIV.
Mitochondrial movement in neurites of 3xTg-AD cortical neurons at 7-9 DIV and effect of
(+)SKF-10,047
Mitochondrial velocity was measured before and one hour post-treatment with vehicle or
1 μmol/L (+)SKF-10,047 in nonTg and 3xTg-AD neurons at 7-9 DIV (Fig. 2.4A). The pretreatment velocity of mitochondria in 3xTg-AD cultures was significantly lower than nonTg
cultures (t(10) = 12.9, p<0.0001) (Fig. 2.4B). Two-way ANOVA revealed a significant effect of
both genotype (F(1,8) = 72.8, p<0.0001) and (+)SKF-10,047 treatment (F(1,8) = 20.67,
p=0.0019) on mitochondrial velocity in cultured cortical neurons (Fig. 2.4C). There was no
significant interaction between the effects. NonTg cultures exhibited markedly higher velocities
of mitochondrial movement compared to 3xTgAD cultures under either treatment condition (Fig.
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2.4C; upper inset). Additionally, (+)SKF-10,047-treated cultures exhibited markedly higher
velocities of mitochondrial movement compared to vehicle-treated cultures (Fig. 2.4C; lower
inset).
Effect of (+)SKF-10,047 on mitochondrial structure and number in cortical neurons at 7-9 DIV
Mitochondrial number and structure measurements were taken one hour post-treatment
with vehicle or 1 μmol/L (+)SKF-10,047 in nonTg and 3xTg-AD cultures (Supplementary Fig.
2.3A). Two-way ANOVA of mitochondrial length showed a significant interaction between
genotype and treatment (F(1,8) = 7.122, p=0.0284). Probing this significant interaction, (+)SKF10,047 treatment significantly increased length in nonTg cultures (t(4) = 3.237, p=0.0318) but
not in 3xTgAD cultures (Supplementary Fig. 2.3B). There was a main effect of genotype on
mitochondrial width (F(1,8) = 30.25, p=0.0006) such that DIV7-9 3xTg-AD cultures were wider
than nonTg cultures regardless of treatment condition (Supplementary Fig. 2.3C). There was a
main effect of (+)SKF-10,047 treatment on roundness (F(1,8) = 24.54, p=0.0011) such that
(+)SKF-10,047 significantly reduced roundness in both nonTg and 3xTg-AD cultures
(Supplementary Fig. 2.3D). There was a significant interaction (F(1,8) = 13.4, p=0.0064)
between genotype and treatment on mitochondrial number. NonTg cultures had no significant
change in number after (+)SKF-10,047 while 3xTg-AD cultures trended toward increased
number (t(4) = 2.57, p=0.0620) at one hour post-treatment (Supplementary Fig. 2.3E).
DISCUSSION
This study demonstrates that 3xTg-AD primary cortical neurons have reduced
mitochondrial number and movement at both 7-9 DIV and 12-14 DIV compared to nonTg
controls. This observation adds to growing evidence that mitochondrial abnormalities early in
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life, perhaps even during development, are a key pathological feature of AD. One complication
of traditional Aβ- and phospho-tau-centric hypotheses of AD pathophysiology is the fact that a
subset of people develop AD pathology without cognitive symptoms [6]. It has been proposed
that individuals with a more extensive “cognitive reserve” or “metabolic reserve” are resistant to
clinical symptoms of AD in the face of AD pathology [111, 112]. These hypotheses focus on
environmental influences on setting up cognitive and metabolic reserves, but it is also possible
that early developmental factors could be involved.
Reduction in mitochondrial movement was the most pronounced difference between
3xTg-AD primary cortical neurons and nonTg controls. At 12-14 DIV, about half as many
mitochondrial movement events occurred in neurites of 3xTg-AD cultures compared to nonTg
controls. We also observed a large reduction in average mitochondrial velocity in neurites of
3xTg-AD neurons when examined at 7-9 DIV. Reduction in mitochondrial movement could lead
to problems with distribution of mitochondria at proper locations along axons and dendrites,
which could negatively impact synaptic transmission [107]. These deficits, over time, could
potentially contribute the loss of synapses seen in AD.
Mitochondrial number was also consistently reduced in 3xTg-AD primary cortical
neurons, which had about three-fourths the number of mitochondria per square micron of culture
compared to nonTg controls. There was not a significant difference in the number of neuronal
cell bodies between 3xTg-AD and nonTg cultures at either 7-9 DIV or 12-14 DIV (data not
shown). An early reduction in mitochondrial number and/or function could be detrimental to
survival and normal differentiation of neurons. Some of the hallmarks of AD, including loss of
synapses and reduction in grey matter volume, would be expected consequences of early
mitochondrial dysfunction in neurons. Additional studies of changes in mitochondrial number in
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both the 3xTg-AD mouse and human patients at various stages of disease could help to
determine if reduced mitochondrial number is a factor in the pathogenesis of AD. Additionally,
studies which elucidate the mechanisms responsible for reduced mitochondrial number in 3xTgAD primary neurons are needed.
Mitochondrial structure also differed between nonTg and 3xTg-AD primary cortical
neurons, depending on time in vitro, but these differences were not as marked as differences in
movement or number. 3xTg-AD cultures at 12-14 DIV had significantly shorter and rounder
mitochondria. This would be expected given previous observations that exogenous treatment
with Aβ oligomers causes reduced mitochondrial length [18, 19], although the change in the
current study was not as marked as the change with exogenous Aβ application. On the other
hand, reduction in mitochondrial length and increased roundness were not present at 7-9 DIV.
Because Aβ expression increases with time in culture for 3xTg-AD neurons [105], it is possible
that mitochondrial length reduction is dependent on the amount of intracellular Aβ present. We
speculate that mitochondrial structural changes at 7-9 DIV could have been compensatory for the
reduction in mitochondrial number.
Reversing mitochondrial abnormalities early in development could be a promising
strategy for preventing the cascade of events that leads to clinical dementia later in life, including
loss of synapses. The σ1R agonist (+)SKF-10,047 significantly increased mitochondrial
movement in both nonTg and 3xTg-AD cortical neurons. In 3xTg-AD neurons there was a more
than two-fold increase in mitochondrial velocity, which brought the final velocity closer to the
baseline nonTg average velocity. The mechanism of this increase is unclear, but it is possible
that the enhancement of mitochondrial function caused by sigma-1 receptor activation [86, 87]
could be responsible for the increased movement. Additionally, sigma-1 receptors are known to
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translocate from the MAM to other membrane compartments of the cell, including mitochondria,
upon stimulation with an agonist. Sigma-1 receptors could potentially interact with proteins
within or adjacent to the mitochondrial membrane involved in mitochondrial translocation
including dynein, members of the kinesin-1 family, and mitochondrial rho (MIRO) proteins
among others. Of these, MIRO1 and MIRO2, which serve as adaptor proteins linking
mitochondria to kinesin, are particularly promising candidates. It has been shown that sigma-1
receptors bind to Rac1 GTPase in isolated brain mitochondria with increased binding after
stimulation with sigma-1 agonists [113]. Sigma-1 receptor binding to MIRO could enhance
movement by stabilizing MIRO-kinesin binding or increasing kinesin activity. Future studies are
needed to document this.
(+)SKF-10,047 also led to a trend of increased mitochondrial number in 3xTg-AD
neurons at 7-9 DIV after one hour of treatment. This increase occurred too fast to be explained
by mitochondrial biogenesis which relies on gene expression from nuclear DNA and protein
production in the cytosol [114]. It is possible that reduced mitophagy triggered by sigma-1
receptor activation could lead to increased mitochondrial number, as inhibition or loss of sigma-1
receptors has been shown to increase mitophagy [115]. Perhaps a change in fission/fusion
dynamics could be occurring, but this would be expected to cause mitochondrial structure
changes; (+)SKF-10,047 had minimal effects on mitochondrial structure in both nonTg and
3xTg-AD cortical neurons. One final possibility is that (+)SKF-10,047 increased mitochondrial
membrane potential. Because Mitotracker® Red-CMXRos fluorescence intensity depends on
mitochondrial membrane potential [116], an increase in mitochondrial membrane potential could
cause previously undetected depolarized mitochondria to increase their signal.
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The effects of (+)SKF-10,047 on mitochondrial movement and number observed in
primary neurons warrant future studies of the mechanisms of action of sigma-1 receptors in
relation to mitochondrial movement, biogenesis, and function. The potential mechanisms of
action of (+)SKF-10,047 on increasing mitochondrial movement should be evaluated, including
effects on mitochondrial ATP production and interaction with mitochondrial motor proteins. The
relationship of reduced mitochondrial number and movement to ER stress should also be
examined, as ER stress markers are increased in 3xTg-AD mice as early as 2 months of age
[117]. Sigma-1 receptors attenuate ER stress [118] and could potentially exert their
mitochondrial effects through this pathway. It should be determined if the effects observed in the
current study are limited to cultured primary cortical neurons or if they are seen in other cell
types in vitro, such as glia or hippocampal neurons. Further, in vivo studies should be carried out
to determine if sigma-1 receptor agonists similarly increase mitochondrial number in neurons in
healthy or diseased states and inform their potential use as pharmacological agents to counteract
mitochondrial damage associated with neurodegenerative diseases.
Mitochondrial number and movement deficits, such as those seen in 3xTg-AD primary
cortical neurons, could be an early initiating factor for synaptic dysfunction and neuronal loss
later in life. A caveat of this conclusion is that APP, Aβ, and phospho-tau accumulation in the
3xTg-AD mouse is driven by transgenes which are not present in the vast majority of sporadic
AD cases in humans. Other developmental insults to mitochondria, however, may still
potentially hinder the establishment of cognitive and metabolic reserves and increase risk of AD
neurodegeneration later in life. For example, germline mitochondrial DNA mutations have been
found to cause premature aging and marked cortical and hippocampal abnormalities in adult
mice [119]. Our study provides evidence of early mitochondrial abnormalities in a model of
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familial AD. Our findings suggest that early treatment with sigma-1 receptor agonists could help
ameliorate AD-associated mitochondrial movement and number deficits at critical stages of
neurogenesis and neuronal differentiation.
One limitation of this study is that we did not differentiate between axons and dendrites.
Mitochondria are significantly smaller and occupy a lower percentage of axons compared to
dendrites [33], and mitochondria move more often and faster in axons compared to dendrites [33,
120]. We attempted to overcome this limitation by sampling an adequate number of fields of
view and sampling consistently between different cultures so that an equal proportion of axons
and dendrites were represented among samples. Another limitation is the inability to directly
compare the cultures at 7-9 DIV and 12-14 DIV. Mitochondria are longer and move less in
cultures at higher DIV [121]. There is also a significantly higher density of mitochondria in
culture at 12-14 DIV compared to 7-9 DIV. We were able to use MT-Red to analyze structure at
both time points, but we could not do individual tracking of mitochondria with MT-Red at 12-14
DIV as we did at 7-9 DIV due to the high number of mitochondria. Therefore we used pDsRed2Mito-transfected cultures for measurement of mitochondrial movement using ROIs. One caveat
of this method is that there is a difference in events/min depending on the distance of the ROI
from the cell body. To overcome this, we measured ROIs in the same range of distances from the
cell body in nonTg and 3xTg-AD neurons.
CONCLUSIONS
Mitochondrial movement and number deficits were observed in primary cortical neurons
derived from embryonic 3xTg-AD mice. These, along with previously observed early
mitochondrial function deficits [70], could be key initiating factors in the development of AD
pathology later in life. Early mitochondrial deficits could also predispose individuals to reduced
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cognitive or metabolic reserve, which relate to clinical severity of cognitive decline in the face of
AD pathology. Pharmacological amelioration of mitochondrial function, number, and movement
deficits early in the development of AD could be a promising strategy for prevention and
treatment of cognitive impairment. The current study provides evidence that σ1R agonists could
be useful agents to restore mitochondrial movement and number in AD neurons in addition to
their known neuroprotective effects. More preclinical studies are needed to elucidate the impact
of early mitochondrial deficits in AD and to develop novel treatment strategies to counteract
these deficits.
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Figure 2.1. Mitochondrial structure and number in DIV12-14 primary cortical cultures.
(A) Sample fields of view from nonTg and 3xTg-AD primary cortical cultures stained with
Mitotracker® Red CMXRos at 12-14 DIV. Scale bars = 20 microns. (B) Higher magnification
views of cultures. Scale bars = 20 microns. (C) Mitochondrial length. (D) Mitochondrial width.
(E) Mitochondrial roundness (width/length). (F) Mitochondrial number per square micron. n=11
nonTg, n=11 3xTg-AD cultures; bar graphs show means + SEM; #p<0.10; ***p<0.001;
****p<0.0001.
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Figure 2.2. Mitochondrial movement in DIV14 primary cortical cultures. (A) Representative
regions of interest within neurites of pDsRed2-mito-transfected nonTg and 3xTg-AD primary
cortical neurons imaged at 14 DIV (Left). Scale bars = 5 microns. Maximum fluorescence
intensity within regions of interest over first 15 min of imaging (Right). (B) Representative
nonTg neuron showing locations of regions of interest for sampling mitochondrial movement.
Scale bar = 50 microns. (C) Number of mitochondrial movement events / minute in regions of
interest. A movement event is defined by an increase or decrease in maximum fluorescence
intensity of ≥ 200 fluorescence units over ≤ 30 seconds corresponding to movement into or out
of a region of interest. (D) Number of mitochondrial transits / minute in regions of interest. A
mitochondrial transit is defined as an event in which an individual mitochondrion passes
37

completely through a region of interest. n=8 nonTg, n=7 3xTg-AD cultures; bar graphs show
means + SEM; *p<0.05; **p<0.01.
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Figure 2.3. Mitochondrial structure and number in DIV7-9 primary cortical cultures. (A)
Sample fields of view from nonTg and 3xTg-AD primary cortical cultures stained with
Mitotracker® Red CMXRos at 7-9 DIV. Scale bars = 20 microns. (B) Higher magnification
views of cultures. Scale bars = 20 microns. (C) Mitochondrial length. (D) Mitochondrial width.
(E) Mitochondrial roundness (width/length). (F) Mitochondrial number per square micron. n=6
nonTg, n=6 3xTg-AD cultures; bar graphs show means + SEM; **p<0.01; ****p<0.0001.
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Figure 2.4. Mitochondrial movement in DIV7-9 primary cortical cultures. (A) Movement
traces of nonTg and 3xTg-AD neurons one hour post-vehicle (Veh) or 1 μmol/L (+)SKF-10,047
(SKF) treatment. Scale bars = 4 microns. (B) Pre-treatment mitochondrial velocity of nonTg and
3xTg-AD cultures. n=6 nonTg, n=6 3xTg-AD cultures. (C) (Left) Mitochondrial velocity in
nonTg and 3xTg-AD cultures one hour post-treatment with vehicle (Veh) or 1 μmol/L (+)SKF10,047 (SKF). Insets (Right) show main effects of genotype (Top) and treatment (Bottom). n=3
cultures per group; bar graphs show means + SEM; **p<0.01; ****p<0.0001.
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Supplemental Figure 2.1. Measurement of mitochondrial structure in primary cortical
cultures. (A) Raw images (Left) of cultures and corresponding binary masks (Right) of
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mitochondria (Green) segmented using a Matlab structural analysis program. Small or large
bodies (Pink) that were excluded from analysis. (B) Field of view containing putative glial cell as
defined by lack of extended neurites and presence of reticular perinuclear mitochondrial
network. Such fields of view were excluded from analysis. Scale bars = 20 microns.
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Supplemental Figure 2.2. Mitochondrial movement and mitochondrial transit events. (A)
Example of two mitochondrial movement events as defined by an increase or decrease in
maximum fluorescence intensity of ≥ 200 fluorescence units over ≤ 30 seconds. One event is
represented by movement into and one by movement out of the region of interest. (B) Example
of a mitochondrial transit, as defined by a mitochondrial movement event in which an individual
mitochondrion passes completely through a region of interest. Regions of interest = 1.1 microns
x 6 microns; Scale bars = 5 microns.
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Supplemental Figure 2.3. Effect of (+)SKF-10,047 on mitochondrial structure and number
in DIV7-9 primary cortical cultures. (A) Sample fields of view from nonTg and 3xTg-AD
primary cortical cultures stained with Mitotracker® Red CMXRos, imaged one hour post-vehicle
(Veh) or 1 μmol/L (+)SKF-10,047 (SKF) treatment. (B) Average mitochondrial length. (C)
Average mitochondrial width. (D) Average mitochondrial roundness (width/length). (E) Average
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mitochondrial number per square micron. n=3 cultures per group; bar graphs show means +
SEM; #p<0.10; *p<0.05; **p<0.01; ***p<0.001.
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Chapter 3

Mitochondrial Structure and Number in
Cortical and Hippocampal Neurons of Aged
3xTg-AD Mice
John Z. Cavendish, Saumyendra N. Sarkar, Mark A. Colantonio,
Dominic D. Quintana, Sujung Jun, and James W. Simpkins
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Abstract:
Mitochondrial dysfunction is observed early in the development and consistently throughout the
course of Alzheimer’s disease (AD). Mitochondrial number and structural abnormalities have
been observed in human AD patients and AD mouse models in cortical and hippocampal neurons
in areas related to AD pathology. Previous studies of mitochondrial morphology in AD have
utilized mostly electron microscopy, which has the advantage of providing ultrastructural detail
but lacks the ability to examine large numbers of mitochondria across a wide range of brain
areas. In the current study, we crossed mice expressing mitochondrially targeted cyan fluorescent
protein (mito-CFP) with triple-transgenic Alzheimer’s disease (3xTg-AD) mice through
successive breeding of offspring to create homozygous 3xTg-AD-CFP mice and nonTg-CFP
controls. We used confocal microscopy of coronal brain sections to study mitochondrial number,
volume, and sphericity in the primary motor cortex (M1), primary somatosensory cortex (S1),
anterior cingulate cortex (AC), entorhinal cortex (EC), and CA1 region of the hippocampus in
24-month mice at the latest stages of AD pathology. We also studied mitochondrial structure and
number in anatomically-defined subregions of the CA1 and dentate gyrus areas of the
hippocampus. We found structural differences in the AC and CA1, particularly in the stratum
radiatum layer. We did not observe any difference in mitochondrial number between AD and
nonTg mice in any of the areas examined. These results provide evidence that metabolic
deficiencies in AD are likely the result of declining mitochondrial function, not number, and that
mitochondrially targeted treatments may be able to alleviate AD symptoms even late in disease
progression.
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Introduction:
Mitochondrial dysfunction is a known pathological hallmark of Alzheimer’s disease
(AD). AD patients show reductions in cerebral glucose metabolism in areas associated with AD
pathology including hippocampus, parietotemporal cortex, and cingulate cortex years before the
onset of AD symptoms [3]. Homologous regional alterations in brain metabolism are seen early
in life in the triple-transgenic Alzheimer’s disease (3xTg-AD) mouse model of AD, and by 18
months all brain areas show reduced glucose metabolism [67]. Human AD patients also show
alterations in TCA cycle enzymes in the brain including reduced activity of pyruvate
dehydrogenase, isocitrate dehydrogenase, and alpha-ketoglutarate dehydrogenase and increased
activity of succinate dehydrogenase and malate dehydrogenase [68, 69]. These alterations
correlate strongly with the clinical stage of disease. The 3xTg-AD mouse similarly shows
reduced pyruvate dehydrogenase protein levels and mitochondrial respiration in the brain as
early as 3 months of age and reduction in mitochondrial respiration of embryonic hippocampal
neurons [70].
In addition to alterations of levels and activity of mitochondrial enzymes, many other
mechanisms may underlie AD-associated metabolic deficits. Studying mitochondrial structure,
number, and distribution in AD neurons is a robust way to provide more insight into multiple
mechanistic pathways, including reduced mitochondrial biogenesis, alteration of fission-fusion
dynamics, and impairment of mitochondrial translocation to distal cellular compartments. Two
studies of AD patients showed reduction in number of neuronal mitochondria [14, 76]. Changes
to neuronal mitochondrial structure, including reduced mitochondrial size, were seen in the
hippocampus, auditory cortex, and frontal cortex, as well as several other non-AD associated
brain areas of AD patients [76]. Abnormal mitochondrial structure, including paracrystalline
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inclusions between mitochondrial cristae and increased matrix density, was also seen in dendrites
of neurons in the frontal cortex of AD patients [77]. Interestingly, the presence of abnormal
mitochondria in this study coincided with cortical areas with more severe dendritic degeneration.
One study described a unique mitochondrial structural phenotype resembling “mitochondria on a
string” in the hippocampus and entorhinal cortex of human AD patients as well as in the
hippocampus of various strains of transgenic AD mice [78]. An in vivo study of mitochondrial
structure in APP/PS1 mice showed reduced mitochondrial density and abnormal mitochondrial
structure in the immediate vicinity of amyloid plaques [79].
A limitation of previous studies of mitochondrial structure and function in AD is the
relatively narrow selection of mitochondria imaged in limited brain regions. Electron microscopy
samples and in vivo imaging fields contain numbers of mitochondria on the order of hundreds,
which represent only a small portion of total mitochondria. The purpose of our current study was
to examine mitochondrial structure, number, and distribution in neurons of various brain areas in
a more widespread and inclusive manner. To achieve this, we created crosses of 3xTg-AD mice
[23] with mice expressing cyan fluorescent protein (CFP) targeted to a subunit of cytochrome c
oxidase and under control of the Thy1 promotor [42]. Using these 3xTg-AD-CFP mice and nontransgenic-CFP (nonTg-CFP) mice derived from the same lineage, we were able to measure
structure and number in large samples of mitochondria in various brain areas and identify
alterations in 3xTg-AD mice at 24 months during the most severe stage of disease. We chose to
examine the CA1 region of hippocampus, entorhinal cortex (EC), and anterior cingulate cortex
(AC) as areas associated with a high amount of AD pathology. We chose the primary motor
cortex (M1) and primary somatosensory cortex (S1) as areas not traditionally affected as heavily
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by AD pathology. We also carried out a more detailed analysis of mitochondrial structure and
number in anatomically defined layers of the CA1 and dentate gyrus regions of the hippocampus.
Based on previous studies, we hypothesized that 3xTg-AD mice would show reduced
number and volume of mitochondria and increased mitochondrial sphericity in neurons of CA1,
EC, and AC, with no difference in number or structure in M1 and S1. We also hypothesized that
mitochondrial structural and number alterations in 3xTg-AD mice would be more severe in the
stratum radiatum of the CA1 where distal pyramidal dendrites exist compared to the pyramidal
layer where pyramidal cell bodies exist due to reduced capacity for AD mitochondria to travel
from their site of biogenesis in the cell body to distal dendrites. We hypothesized there would be
fewer alterations in mitochondrial structure and number in the dentate gyrus regions due to
relatively lower burden of AD pathology compared to CA1.
Materials and Methods:
Mice
Animal protocols were performed in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of West Virginia University. Homozygous 3xTg-AD mice
(B6;129-Tg(APPSwe,tauP301L)1Lfa Psen1tm1Mpm/Mmjax; stock number 34830-JAX) and mitoCFP mice (B6.Cg-Tg(Thy1-CFP/COX8A)S2Lich/J; stock number 007967) [42] were obtained
from The Jackson Laboratory, and colonies were bred and maintained at West Virginia
University. Animals were housed in cages of up to five animals on a 12 h light cycle with ad
libitum access to food and water.
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To obtain animals used in the study, homozygous female 3xTg-AD mice were crossed
with homozygous male Mito-CFP mice to obtain F1 heterozygotes. F1 heterozygotes were bred
to obtain F2 mice of various genotypes which were selectively bred to obtain F3 homozygous
3xTg-AD Mito-CFP (AD-CFP) mice and nonTg Mito-CFP (nonTg-CFP) mice from which
additional F4 homozygotes were bred. We used the following genotypes in F2 to breed the
desired F3 AD-CFP homozygotes: (1) CFP+/+, Ps1+/+, APP/Tau+/-; (2) CFP+/+, Ps1+/-, APP/Tau+/+;
(3) CFP+/+, Ps1+/-, APP/Tau+/-. We used the following genotypes in F2 to breed the desired F3
nonTg-CFP homozygotes: (1) CFP+/+, Ps1+/-, APP/Tau+/-; (2) CFP+/+, Ps1-/-, APP/Tau+/-; (3)
CFP+/+, Ps1+/-, APP/Tau-/-. Therefore, homozygous nonTg-CFP and AD-CFP mice were both
derived as F3 progeny of the same founder mice, and all mice used in this study were either the
F3 mice or their F4 offspring from crosses between F3 CFP+/+, Ps1+/+, APP/Tau+/+ parents for
AD-CFP mice or F3 CFP+/+, Ps1-/-, APP/Tau-/- parents for nonTg-CFP mice.
Solutions
10x Phosphate buffered saline (PBS) was prepared by dissolving 80g NaCl, 2g KCL,
11.5g Na2HPO4∙7H2O, and 2g KH2PO4 in milliQ water, bringing volume to 1L, and adjusting pH
to 7.5. 1x PBS was made by diluting 10x PBS 1:10 in milliQ water. For 20% paraformaldehyde
(PFA), 80g PFA was dissolved in warm milliQ water and volume was brought to 400mL. 4%
PFA was prepared by mixing 350mL milliQ water, 100mL 20% PFA, and 50mL 10x PBS and
adjusting pH to 7.4. 30% sucrose solution was prepared by dissolving 30g sucrose in 1x PBS and
adjusting volume to 100mL.
Tissue Preparation
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24-month mice were perfused transcardially with 20-30 mL of 1x PBS to remove blood
followed by 25mL 4% PFA solution. Brains were dissected out and post-fixed for 24 hours in
4% PFA. Brains were then washed with 1x PBS and transferred to 30% sucrose solution for 72
hours for cryoprotection. Following cryoprotection, brains were stored at 4oC in 30% sucrose
until slicing. Prior to slicing, olfactory bulbs and cerebellum were removed. Brains were
mounted on a sliding microtome with freezing stage (Thermo) and allowed to freeze fully. 50 μm
coronal slices were made through the entire cortex and collected in 1x PBS. Slices were mounted
onto glass slides in mounting medium (Ibidi) containing 1,4-diazabicyclo[2.2.2]octane
(DABCO) and covered with glass coverslips (0.17 mm thickness). Slides were stored in the dark
at 4oC until imaging.
Imaging
Three representative slices per area containing AC, M1, S1, and entorhinal cortex as well
as CA1 hippocampus were chosen for each animal for imaging (Fig. 3.1D). The slices imaged
for each animal represented the same antero-posterior position in the brain for each area. Areas
were confirmed using the Allen Adult Mouse Brain Atlas. Confocal images were collected using
a Zeiss 710 laser scanning microscope with a 63x Plan Apochromat oil immersion objective
(N.A.=1.4) at an excitation wavelength of 458 nm, laser power of 35.1%, gain of 923, and
digital offset of 44.4. A 465-518nm emission filter was used to collect fluorescence emitted from
CFP. Z-stacks were collected through the entire thickness of the slice at an interval of 0.39 μm.
1024x1024 resolution images were acquired with xy pixel scale of 0.132 μm/pixel to give an
imaging field of view of 135 x 135 μm2. For comparisons of 24-month AD-CFP vs. nonTg-CFP
mice, a single field of view was captured for each slice giving a total of 3 fields of view for each
imaging area. For subregion analysis of the hippocampus, 10x3 stitched z-stacks were captured
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encompassing a central strip of CA1 and dentate gyrus. The hippocampal region imaged for
subregion analysis was on the opposite side of the slice as the area used for single field of view
imaging so that no part of CA1 was sampled more than once.
Data Analysis
Single Field of View Images
Zeiss images were converted to stacks of 8-bit Tiffs and imported into ImageJ (NIH). A
substack of 60 images (23.4 μm) was selected starting from the first plane fully encompassing
the sample with no hole-artifacts at the cut surface of the tissue. Images were despeckled and
background subtraction (rolling ball radius = 10 pixels) was performed. Processed Tiff stacks
were exported to Imaris (Bitplane) for 3D rendering. The surface function was used to segment
mitochondria in 3D-rendered images with auto-thresholding enabled. A filter was used to
exclude objects with volume ≤ 0.10 μm3 which represent noise. The volume and sphericity of
each object were measured as well as the total number of objects present. Average object volume
and sphericity for each imaging area were calculated by pooling the measurements of objects
from the 3 slices imaged and taking the grand average. Average number of objects was
calculated by averaging the three measurements of number of objects for each area.
Subregions of CA1 and Dentate Gyrus
Stitched images were cropped into regions representing five subregions (Stratum OriensSO, Pyramidal Layer-Pyr, Superficial Stratum Radiatum-SRs, Deep Stratum Radiatum-SRd,
Stratum Lacunosum Moleculare-SLM) for CA1 (Fig. 3.2) and three subregions (Molecular
Layer-Mol, Granular Layer-Gr, and Subgranular Layer-SG) for dentate gyrus (Fig. 3.4). Each
rectangle represented the same imaging volume of one field of view used in the single-field-of53

view analysis. Cropped zeiss images were converted to stacks of 8-bit Tiffs and exported to
ImageJ (NIH). A substack of 60 images (23.4 μm) was selected starting from the first plane fully
encompassing the sample with no hole-artifacts at the cut surface of the tissue. Images were
despeckled and background subtraction (rolling ball radius = 10 pixels) was performed.
Processed Tiff stacks were exported to Imaris (Bitplane) for 3D rendering. The surface function
was used to segment mitochondria in 3D-rendered images with auto-thresholding enabled. A
filter was used to exclude objects with volume ≤ 0.10 μm3 which represent noise. The volume
and sphericity of each object were measured as well as the total number of objects present.
Average object volume and sphericity for each imaging area were calculated by pooling the
measurements of objects from the 3 slices imaged and taking the grand average. Average number
of objects was calculated by averaging the three measurements of number of objects for each
area.
Statistical Analysis
Investigators performing imaging and image analysis were blinded to age and genotype.
All statistical analyses were performed using Prism version 7.04 (GraphPad). Two-tailed
unpaired t-tests were used to assess the effect of genotype on mean mitochondrial volume,
sphericity, and number per imaging field with a significance level of p<0.05. For single field-ofview analyses, n=5 24-month nonTg-CFP mice and n=4 24-month 3xTg-AD-CFP mice. For
subregion analyses, n=3 24-month nonTg-CFP mice and n=3 24-month 3xTg-AD-CFP mice.
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Results:
Mitochondrial number, volume, and sphericity in neurons of 24-month 3xTgAD and nonTg mice.
There was no difference between 24-month 3xTg-AD and nonTg mice in number of
mitochondria per imaging volume in any of the four cortical or one hippocampal region imaged
(Fig. 3.1A). Across all areas, 3xTg-AD mice trended towards more mitochondria, but also had
more variability in mitochondrial number than nonTg mice. Mitochondrial volume was
significantly higher in the AC cortex of 3xTg-AD mice by about 33% (t(7) = 2.869, p = 0.024)
and significantly lower in the CA1 hippocampus of 3xTg-AD mice by about 20% (t(7) = 2.024,
p = 0.041) (Fig. 3.1B). Conversely, mitochondrial sphericity was significantly lower in neurons
of AC cortex (t(7) = 5.738, p = 0.0007) and higher in neurons of CA1 hippocampus (t(7) =
2.424, p = 0.046) of 3xTg-AD mice (Fig. 3.1C). There were no differences in mitochondrial
volume or sphericity in M1, S1, or EC. Mitochondria of the CA1 hippocampus in both genotypes
tended to be smaller, more numerous, and more spherical than mitochondria of the four cortical
areas examined.
Mitochondrial number, volume, and sphericity in hippocampal subregions of 24-month 3xTgAD
and nonTg mice
There was no significant difference between 3xTg-AD and nonTg mice in mitochondrial
number in any subregion of CA1 (Fig. 3.2; Fig. 3.3A) or dentate gyrus (Fig. 3.4; Fig. 3.5A).
Mitochondrial volume was significantly reduced in 3xTg-AD mice in neurons of both SRs (t(4)
= 2.475, p = 0.034) and SRd (t(4) = 4.852, p = 0.008), but there were no differences in SO, Pyr,
or SLM (Fig. 3.3C). The only CA1 area with a significant difference in mitochondrial sphericity
was SO, where 3xTg-AD mice had significantly more spherical mitochondria (t(4) = 3.474, p =
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0.026) (Fig. 3.3B). Mitochondria of the SLM had markedly higher volume and were less
numerous than any of the other four areas of CA1 in both genotypes (Fig. 3.3A,D). There were
no differences in mitochondrial number, volume, or sphericity between 3xTg-AD and nonTg
mice in any subregion of the dentate gyrus (Fig. 3.5A-C), but Gr had fewer mitochondria of
higher volume than Mol or SG in both genotypes (Fig. 3.5A,B).
Discussion:
Mitochondrial structural changes in CA1 and AC were observed in neurons of 24-month
3xTg-AD mice compared to nonTg mice in the absence of difference in mitochondrial number.
The reduction in mitochondrial volume and increase in mitochondrial sphericity in CA1 supports
previous data showing hippocampal mitochondrial structural abnormalities in the hippocampus
of AD patients and 3xTg-AD mice [76, 78]. Contrary to these studies, however, was the fact that
nonTg mice showed relatively small, spherical neuronal mitochondria in the dendritic
compartment (SRs and SRd) in comparison to the long, rod-shaped mitochondria expected.
Mitochondria in the cell body compartment (Pyr), however, exhibited the expected rod-shaped
morphology. The increased mitochondrial volume and decreased sphericity in 3xTg-AD mice
within AC neurons might be the consequence of mitochondrial inclusions within the matrix as
described in frontal cortical dendrites of AD patients [77]. More detailed electron microscopy
studies in 3xTg-AD-CFP mice could help determine if this were the case. The lack of differences
in neuronal mitochondrial structure or number in 3xTg-AD mice compared to nonTg mice at 24months in M1 and S1 was expected, but was unexpected in EC as this is one of the first and most
severely affected regions in AD. It is possible that the lack of observed mitochondrial pathology
could be due to bias of imaging only the neurons which survived the AD pathology up to 24
months of age, and that neurons with more severe mitochondrial pathology had already died.
56

Even if this were the case for a small population of neurons, it is unlikely that this bias had a
large effect in our study as there was no observed difference in density of neuronal cell bodies
between 3xTg-AD and nonTg mice in our study. Further, significant hippocampal or cortical
atrophy and/or neuron loss are not reported in 3xTg-AD mice despite development of AD
pathology [122].
There are several possible confounding factors in the interpretation of the results of this
study. One is that it is unknown whether expression of mito-CFP alters mitochondrial structure
or number. Few antibodies exist for immunohistochemical staining of mitochondria in fixed
tissue samples, and none of them produce a clear enough signal for detailed structural analysis of
individual mitochondria via light microscopy. Therefore it was not possible to compare nonCFP-expressing mice with CFP-expressing mice using the microscopy methods from this study.
An alternative option would be to perform electron microscopy analysis of mitochondrial
structure and number in non-CFP-expressing mice compared to CFP-expressing mice, but the
sampling region would be necessarily limited.
Another possible limitation to this study was that mitochondrial structure may be altered
during the perfusion and fixation process. There is a necessary, yet brief exposure of neurons to
hypoxia during desanguination and before fixation, which may induce a structural response in
mitochondria such as that seen in primary astrocytes [123]. Also, fixation at room temperature,
as was performed in this study, has been shown to reduce mitochondrial length in cultured cells
compared to fixation at 37oC [110]. It is possible to image mitochondria in the cortex of live,
anesthetized mito-CFP mice through a cranial window [124], so future studies might be able to
elucidate the differences in mitochondrial structure and number in live neurons versus fixed
tissue to avoid these issues.
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Overall, this study showed differences in mitochondrial structure in the CA1 and AC of
3xTg-AD mice at the most severe stage of disease without differences in mitochondrial number.
Previous human and mouse studies which found significant mitochondrial \ number changes in
AD were based on observations of relatively few mitochondria using electron microscopy. The
strength of this study was its inclusion of a vast number of neuronal mitochondria with unbiased
sampling, and may indicate that previously observed mitochondrial structure and number
alterations might be local phenomena in certain subpopulations of neurons. This study supports
the conclusion that metabolic deficits in the AD brain are more heavily related to mitochondrial
function than number. This gives promise to the prospect of using pharmacotherapy to restore
mitochondrial energy production, as the requisite mitochondria are likely still present even at
advanced stages of pathology.
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Fig. 3.1. Neuronal mitochondrial number, volume, and sphericity in 24-month 3xTgAD and
nonTg mice. (A) Number of objects per imaging volume. (B) Mitochondrial volume. (C)
Mitochondrial sphericity. Values are mean ± standard error. * p < 0.05; *** p < 0.001. n = 5
(WT); n = 4 (3xTgAD). (D) Representative images of brain areas showing neuronal
mitochondria (cyan). AC- Anterior Cingulate Cortex; M1- Primary Motor Cortex; S1- Primary
Somatosensory Cortex; CA1- Hippocampus; EC- Entorhinal Cortex. Scale bars = 10μm
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Fig. 3.2. Mitochondria in subregions of CA1 in 24-month 3xTgAD and nonTg mice. (A)
Cross-section of hippocampus showing location and size of subregions. Scale bars = 100μm (B)
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Subregions of CA1; SO-Stratum Oriens; Pyr-Pyramidal Layer; SRs-Superficial Stratum
Radiatum; SRd-Deep Stratum Radiatum; SLM-Stratum Lacunosum Moleculare. Scale bars =
10μm (SO, SRs, SRd, and SLM); Scale bars = 15μm (Pyr).
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Fig. 3.3. Neuronal mitochondrial number, volume, and sphericity in CA1 Subregions of 24month 3xTgAD and nonTg mice. (A) Number of objects per imaging volume. (B)
Mitochondrial sphericity. (C-D) Mitochondrial volume. Values are mean ± standard error. * p <
0.05, ** p < 0.01. n = 5 (WT); n = 4 (3xTgAD).
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Fig. 3.4. Mitochondria in subregions of dentate gyrus in 24-month 3xTgAD and nonTg
mice. (A) Cross-section of hippocampus showing location and size of subregions. Scale bars =
100μm (B) Subregions of dentate gyrus; Mol-Molecular Layer; Gr-Granular Layer; SGSubgranular Layer. Scale bars = 10μm.
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Fig. 3.5. Neuronal mitochondrial number, volume, and sphericity in dentate gyrus
subregions of 24-month 3xTgAD and nonTg mice. (A) Number of objects per imaging volume
(B) Mitochondrial volume. (C) Mitochondrial sphericity. Values are mean ± standard error. * p <
0.05. n = 5 (WT); n = 4 (3xTgAD).
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Discussion
Because of the high dependence upon mitochondrial energy production in neurons and
the unique challenges posed to neuronal mitochondria, neurons are especially susceptible to
degeneration following mitochondrial dysfunction. Previous work has suggested that
mitochondria are abnormal in function, morphology, number, and dynamics early in and
consistently throughout the course of AD. Some have hypothesized that mitochondria are
critically involved in the initiation and propagation of sporadic AD, and that declining
mitochondrial function precedes and underlies the development of the other hallmarks of AD
pathology including tau hyperphosphorylation and aggregation, Aβ overproduction, and
neuronal/synaptic loss [17, 125]. Studying the contribution of mitochondrial abnormalities to the
progression of AD and the time-course of their appearance are important in understanding the
full picture of AD pathology and developing new treatment strategies which can protect and/or
restore mitochondrial function at critical stages of AD progression. The failure of amyloid-based
AD treatments initiated late in disease progression underlies the need for new approaches.
Targeting mitochondrial dysfunction early in AD-susceptible individuals should be explored as
part of a multifactorial approach to preventing or slowing the disease. My dissertation research
examined mitochondrial changes at the earliest and latest stages of disease in 3xTg-AD mice.
The results of these studies add to the growing body of work examining the contribution of
mitochondria to AD pathology. Many questions still remain to be examined, and future
preclinical and clinical studies of mitochondria in AD and mitochondria-targeted treatments may
yield new insight and overcome current barriers to slowing or halting AD progression.
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Mitochondrial Changes Early in Development of Alzheimer’s Disease
Our study of embryonic primary cortical neurons of 3xTg-AD mice showed that
mitochondrial movement and number were markedly deficient with modest structural
abnormalities even at the very earliest stages of neuronal development. These observations were
consistent with previous reports that exogenously applied Aβ oligomers could impair
mitochondrial movement and alter mitochondrial structure in primary neurons [18-20]. A
strength of our study is that the endogenous production of Aβ and potential synergistic
interaction with hyperphosphorylated tau in 3xTg-AD neurons more closely mimics the
conditions present in human AD, particularly familial early-onset AD in which genetic mutations
are present embryonically.
An implication of this study is that mitochondrial dysfunction during neuronal
development could predispose individuals to be more susceptible to insults later in life that
ultimately manifest as the neurodegeneration, synapse loss, brain atrophy, and cognitive decline
that are hallmarks of AD. This could be an explanation of the phenomenon that some people do
not develop the clinical symptoms of AD despite the presence of significant AD pathology [5, 6].
Conversely, one study of 430 elderly individuals found that 23 percent showed markers of brain
injury typically associated with AD, such as hippocampal atrophy and reduced cerebral glucose
metabolism, without cerebral amyloid pathology [7]. The authors used the term “suspected nonAlzheimer pathophysiology” (sNAP) to describe this group, and it was notable that they showed
many aspects of brain pathology including regional cerebral hypometabolism that were
indistinguishable from patients classified with stage 2 and 3 preclinical AD.
These observations may be partially explained by the “reserve” hypotheses. “Brain
reserve”, “cognitive reserve”, or “intellectual reserve” are terms interchangeably used to describe
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individuals that have a greater resilience to age-related cognitive decline, even in the face of AD
pathology, due to more numerous neurons initially or increased capacity to recruit remaining
neurons after they begin to degenerate [111, 126-129]. The proposed mechanisms behind
increased cognitive reserve include increased education, increased socioeconomic status, and
improved social networks. A complementary hypothesis of “metabolic reserve” which proposes
that individuals with improved dietary, exercise, or other lifestyle factors are able to resist
cognitive decline in the face of neuropathology due to improved metabolic functioning of
remaining neural networks [112]. This hypothesis is supported by the association of MCI and
AD with poor diet, obesity, type 2 diabetes, and lack of exercise.
While the reserve hypotheses described focus largely on environmental factors
throughout life as being responsible for establishment of cognitive or metabolic reserves, we
propose that early developmental factors may also play a role in establishing cognitive and
metabolic reserves against neurodegenerative changes in AD. Early insults to mitochondrial
number, structure, or function as seen in our study may negatively impact the proper
development of neurons and synapses and lead to reduction in cognitive and/or metabolic
reserves. While our study is most relevant in the case of familial AD due to the presence of
mutant transgenes, other mitochondrial insults early in development could increase the risk for
development of sporadic AD as well. Germline mutations in mitochondrial DNA cause
premature brain aging and abnormalities in the cortex and hippocampus of adult mice [119].
Another possible early mitochondrial insult in the case of sporadic AD is expression of
microRNA 34a. We have shown that microRNA 34a is elevated in the temporal cortex of human
AD patients as well as the temporal cortex and hippocampus of 3xTg-AD mice [130]. Our
preliminary studies showed that microRNA 34a overexpression in primary cortical neurons of
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non-transgenic mice induced mitochondrial structural changes and deficits in mitochondrial
movement (Cavendish et. al; unpublished observation). In primary hippocampal neurons,
microRNA 34a overexpression causes reduction in ATP production, spare capacity, maximum
respiration, and proton leak, and induces downregulation of proteins involved in oxidative
phosphorylation [130]. Transgenic mice inducibly overexpressing microRNA 34a early in life
develop cognitive deficits and AD histopathology in cortical and hippocampal regions (Sarkar et.
al; publication in revision).
The implications of our research suggest that both familial early-onset and sporadic lateonset AD may stem from early impairment of mitochondrial function which diminishes
cognitive/metabolic reserve and increase susceptibility to clinical dementia. This lends support to
the exploration of early treatments to improve neuronal mitochondrial function for the prevention
of AD.
Sigma-1 Receptor Agonists for Treatment of Alzheimer’s Disease
σ1R agonists are promising candidates for treatment of AD early in disease progression
due to their known ability to increase mitochondrial ATP production among other
neuroprotective effects [85]. In our study of mitochondrial deficits in embryonic 3xTg-AD
neurons, we found that σ1R activation by (+)SKF-10,047 can also increase neuronal
mitochondrial movement and partially restore mitochondrial number deficits in 3xTg-AD
neurons.
Although (+)SKF-10,047 is not approved for human use due to side effect profile, other
σ1R agonists are available. ANAVEX2-73 is one such compound and is currently undergoing
phase IIb/III clinical trials for treatment of MCI and early stage AD. Although the primary study
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is not expected to be completed until the end of 2020, the drug has passed its phase I and phase
IIa trials showing high tolerability with minimal side effects. Other approved drugs with σ1R
agonist activity include (+)Pentazocine, used for pain treatment, and dextromethorphan, used as
a cough suppressant and treatment of pseudobulbar effect. Dextromethorphan has been shown to
reduce agitation and aggression in AD patients, but has not been extensively studied as a diseasemodifying agent [131]. Memantine, an approved agent for AD treatment, also has partial σ1R
agonist activity but also does not halt or slow disease progression.
Alzheimer's disease is a multifactorial and heterogeneous disease. σ1Rs may also
alleviate AD through several other pathways. One factor of the pathogenesis of AD not
examined in this dissertation is the contribution of inflammation and glial activation to neuronal
damage and synapse loss [132]. It is known that several genes regulating glial clearance of
misfolded proteins increase risk for sporadic AD [133]. Aβ can bind to several microglial
receptors and activate an innate immune response resulting in release of inflammatory cytokines
and structural damage to neurons or synapses [134]. Increased cytokines also inhibit the
microglial clearance of Aβ from the brain [134]. Pretreatment with σ1R agonists has been shown
to prevent microglial activation and attenuate cytokine release in response to multiple triggers of
inflammation [135].
Oxidative stress is also associated with AD and brains of AD patients show increased
lipid peroxidation [136]. Copper can bind to the n-terminus of Aβ, and the accumulation of
copper in amyloid oligomers and plaques can trigger generation of reactive oxygen species
[136]. Additionally, Aβ accumulation causes increased zinc release and dysregulated zinc
homeostasis in the brain, which also contributes to the increased production of reactive oxygen
species [136]. σ1R agonists were shown to reduce amyloid-induced lipid peroxidation in the
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brains of mice [90] which is consistent with other observations of antioxidant properties of σ1R
activation [85].
New compounds with σ1R agonist activity are continuously being developed which may
provide promising results for early treatment of AD via modulation of mitochondrial activity
among other diverse mechanisms of action [137-139]. More preclinical and clinical studies of
σ1R agonists alone or in combination with other agents to combat AD are warranted.
Preservation of Mitochondrial Structure and Number Late in Alzheimer’s Disease
Our study of aged 3xTg-AD mice showed surprisingly little change in mitochondrial
structure across different brain areas and no change in mitochondrial number compared to nonTg
controls. These findings contrasted with previous studies of human AD patients and AD mice
which reported neuronal mitochondrial structural abnormalities [76-79] and reduction in
neuronal mitochondrial number [14, 76] in cortical and hippocampal areas. We did find a modest
reduction of mitochondrial volume in the CA1 area of the hippocampus in 3xTg-AD mice with
increased sphericity, and it is known that the hippocampus is one of the earliest and most
severely affected regions in AD. Subregion analysis showed that these changes were most
heavily found in the stratum radiatum, where apical dendrites of hippocampal pyramidal neurons
reside. This would be an expected result of reduced mitochondrial replenishment in distal
dendrites due to reduced capacity for mitochondrial movement away from their site of biogenesis
in the cell body, which is supported by in vitro data of primary neurons [18, 19].
M1 and S1 are typically spared from AD pathology, so an absence of mitochondrial
abnormalities in those regions was not entirely unexpected. At 24 months, however, the 3xTgAD mouse shows considerable amyloid staining across the entire cortex and hippocampus
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(Figure 4.1). The lack of mitochondrial structural changes in the EC was unexpected given its
high degree of involvement in AD pathology even at early stages of disease. The increased
volume and reduced sphericity of AC mitochondria in the 3xTg-AD mouse could be consistent
with the development of mitochondrial inclusions as are seen in the frontal cortical dendrites of
AD patients [77].
Together, these findings indicate that mitochondria are largely intact in terms of structure
and number at the latest stages of disease in 3xTg-AD mice. The discrepancies between our
study and previous studies showing structural abnormalities could be due to the different
imaging methods used. Using light microscopy to image large numbers of mitochondria
unbiasedly in larger tissue volumes provided our study an advantage over previous studies which
used electron microscopy to examine relatively small volumes of tissue and numbers of
mitochondria. A disadvantage of our study was the inability to examine ultrastructural details of
mitochondria which may have been present in 3xTg-AD mice.
Our study had several other limitations including the possibility that endogenous
expression of mitochondrially-targeted CFP may have altered mitochondrial structure in both
nonTg and 3xTg-AD mice. We were not able to test mitochondrial structure by light microscopy
in non-CFP mice versus CFP-expressing mice due to lack of available antibodies to label
mitochondria in fixed brain slices. In future studies, it would be possible to accomplish this with
electron microscopy, but these studies were outside the scope of my dissertation work. Another
limitation to this study was the small sample size available for study and the use of multiple ttests which can produce type-1 error. These limitations should be considered in the interpretation
of study results.
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The lack of structural or number abnormalities found in our study suggest that the known
metabolic changes associated with AD [3, 67-70] are likely caused by dysfunction of the
mitochondria that are present. This is promising for the treatment of AD with mitochondriallytargeted therapies even in mid to late stages of disease progression to protect remaining neurons.
Oxaloacetate is the only current agent which specifically targets mitochondria undergoing
clinical trials for AD treatment, and has completed phase I testing. The cerebral metabolic
deficits which appear very early in AD progression combined with known mitochondrial
functional deficits in AD highlight the need for more mitochondria-based treatment strategies.
Mitochondrial enhancement, alone or in combination with other therapies, is a promising avenue
for protecting neuronal function, preventing synapse loss, and slowing or halting the progression
of AD.
Conclusions
In over a century since its first description, AD has been a mysterious disease that has defied
attempts to understand its pathology or produce therapies against it. The increasing elderly
population, failure to develop disease-modifying treatments, and high burden of AD in terms of
quality of life of patients and cost of care make AD one of the fastest growing healthcare
problems of our society. Traditional approaches to treating AD based on amyloid pathology
alone have all failed, and new strategies are needed. My dissertation work focused on
understanding the mitochondrial aspects of AD in the early and late stages of disease. My work
provided insights into the embryonic origins of AD via mitochondrial deficits and suggested σ1R
activation as a potential therapeutic strategy for counteracting these deficits. I was able to show
that mitochondrial structural and number alterations were not as severe as previously expected
late in disease progression, which indicates that mitochondrial treatments may be able to be
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effective at salvaging neuronal function even in the later stages of disease. My preclinical
research will hopefully inform future translational studies that may contribute to the development
of new therapeutic strategies for treating AD and preventing disease progression in susceptible
individuals.

74

Figure 4.1. Amyloid staining in various brain areas of 3xTg-AD mice compared to nonTg
controls at 24 months. Coronal sections stained with anti-β-amyloid 1-16, clone 6E10
(Biolegend) shows considerable intracellular amyloid accumulation as well as extracellular
plaques across cortical and hippocampal areas of 3xTg-AD mice. AC- Anterior Cingulate
Cortex; M1- Primary Motor Cortex; S1- Primary Somatosensory Cortex; EC- Entorhinal Cortex;
CA1- CA1 region of Hippocampus.
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